Fig. 2From: Clinical implication of cellular vaccine in glioma: current advances and future prospectsAutologous dendritic cell/tumor antigen vaccine (ADCTA) in anti-glioma clinical trial. Vaccination with tumor lysate-pulsed dendritic cells (DC) elicits antigen-specific, CD4+/CD8+ cytotoxic T cell responses and induces IFN γ secretion in patients with malignant glioma. The peptide modified DC with cocktail (WT-1, HER2, MAGE-A3, and MAGE-A1 or gp100) had a positively response in HLA-A24+ glioma patientsBack to article page